Moya-Plana et al. (1) suggest neoadjuvant anti-PD1 antibodies as the next step in managing HNMM as the neoadjuvant nivolumab induces significant pathologic response in resectable lung tumors and even in cutaneous melanomas. Here, PDCD1 is linked to cutaneous melanoma.